UvA-DARE (Digital Academic Repository)
Clinical and genetic spectrum of hereditary cardiac arrhythmia syndromes
Bhuiyan, Z.A.
Publication date
2009
Document Version
Final published version
Link to publication
Citation for published version (APA):
Bhuiyan, Z. A. (2009). Clinical and genetic spectrum of hereditary cardiac arrhythmia
syndromes.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s)
and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open
content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please
let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material
inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter
to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You
will be contacted as soon as possible.
UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
Download date:28 Nov 2021
11
Arrhythmogenic Right Ventricular Cardiomyopathy due
to a Novel Plakophilin 2 Mutation: Wide Spectrum of
Disease in Mutation Carriers Within a Family
Prince J. Kannankeril,1* Zahurul A. Bhuiyan,2* Dawood Darbar,3 Marcel M.A.M. Mannens,2 Arthur A.M. Wilde,4 and Dan M.
Roden,3
*The first two authors contributed equally to this work
Department of Pediatrics,1 Vanderbilt University School of
Medicine, Nashville, TN
2
Department of Clinical Genetics, Department of Cardiology,4
Academic Medical Center, University of Amsterdam,
The Netherlands
3
Department of Medicine, Vanderbilt University School of
11
Medicine, Nashville, TN
Heart Rhythm. 2006;3:939-44.
235
Clinical and Genetic Spectrum of Hereditary Cardiac Arrhythmia Syndromes
11
236
Abstract
Background: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a familial
disease, with male preponderance, characterized by progressive fibrofatty replacement of
the right ventricle and ventricular arrhythmias. Mutations in plakophilin-2 (PKP2), a desmosomal protein, have been reported to underlie familial ARVC. We report a novel ARVC
PKP2 mutation and present the clinical findings in 3 female mutation carriers.
Methods and Results: A female proband presented with resuscitated cardiac arrest, and
was diagnosed with ARVC due to right ventricular enlargement and regional hypokinesis,
along with repolarization abnormalities and frequent ventricular ectopy. A novel 28 bp
insertion in exon 11 of the PKP2 gene was found which causes a frameshift in the coding
region. This results in a change in the amino acid sequence of the protein with a premature
stop codon at position 740. Four first degree relatives were screened, and the mother and
younger sister were identified as mutation carriers. The mother was phenotypically normal,
while the younger sister has repolarization abnormalities and frequent ventricular ectopy.
Conclusions: We report a novel PKP2 mutation which causes familial ARVC. All mutation carriers in this kindred were women, and the family showed incomplete penetrance and
variable expression of ARVC. Premature truncation of the plakophilin-2 protein appears to
be the predominant mechanism whereby PKP2 mutations elicit the ARVC phenotpye.
11
Key Words: cardiomyopathy, heart arrest, genetics, arrhythmia, women
Abbreviations
ARVC = Arrhythmogenic right ventricular cardiomyopathy
ECG = electrocardiogram
SAECG = signal-averaged electrocardiogram
MRI = magnetic resonance imaging
PCR = polymerase chain reaction
DHPLC = denaturing high-performance liquid chromatography
Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease characterized by progressive fibrofatty replacement of the right ventricular myocardium and
237
Clinical and Genetic Spectrum of Hereditary Cardiac Arrhythmia Syndromes
ventricular arrhythmias. It affects males disproportionally, and carries an increased risk
for sudden death, particulary during exercise.1,2 ARVC is most commonly inherited in an
autosomal dominant fashion, with significant genetic heterogeneity and at least 9 different
genetic loci mapped.3 To date, 5 genes have been implicated in autosomal dominant ARVC,
including transforming growth factor-β3 (TGFβ3) in ARVC1,4 the cardiac ryanodine
receptor (RYR2) in ARVC2,5 and 3 desmosomal proteins: desmoplakin (DSP) in ARVC8,6
desmoglein-2,7 and plakophilin-2 (PKP2) in ARVC9.8
11
Global
and/or
Regional
Dysfunction
and
Structural
Alterations
Tissue
Characterization
of Walls
Major
Severe
dilatation and
reduction of
RV EF with
no (or only
mild) LV
impairment.
Localized RV
aneurysms.
Severe
segmental RV
dilatation.
Fibrofatty
replacement of
myocardium on
endomyocardial
biopsy
Minor
Global RV
dilatation and
reduced EF
with normal
left ventricle.
Regional
right
ventricular
hypokinesis.
Repolarization
Abnormalities
Depolarization
Abnormalities
Arrhythmias
Epsilon waves or
localized
prolongation
(>110ms) of the
QRS complex in
right precordial
leads.
Inverted T waves
in V2 and V3
Late potentials
on SAECG
Family
History
Familial
disease
confirmed
at
necropsy
or surgery.
LBBB VT on
ECG, Holter,
exercise
testing.
Frequent
ventricular
extrasystoles
(>1000/24
hours)
(Holter.)
Familial
history of
premature
sudden
death due
to
suspected
ARVC.
Familial
history
(clinical
diagnosis
based on
present
criteria.)
RV indicates right ventricle; EF, ejection fraction; LV, left ventricle; SAECG, signal-averaged electrocardiogram;
LBBB, left bundle branch block; VT, ventricular tachycardia; ECG, electrocardiogram; ARVC, Arrhythmogenic
right ventricular cardiomyopathy
Table 1: Diagnostic criteria for Arrhythmogenic Right Ventricular Cardiomyopathy
238
Plakophilins with other proteins assemble to form desmosomes, complex structures which
provide structural and functional integrity to adjacent cells. They are abundant in cells that
experience mechanical stress and appear to have a primarily structural function.9 Plakophilin-2 interacts with multiple other cell adhesion proteins and is the primary cardiac plakophilin.10 Ablation of mouse Pkp2 results in defects of cardiac morphogenesis and junctional
architecture with embryonic lethality.11 It is thought that mutant PKP2 in cardiac desmosomes impairs cell to cell contacts and disrupts adjacent myocytes. Areas of high stress
and stretch are thought to be particularly vulnerable, explaining the focal involvement and
exercise-related risk of arrhythmias in ARVC.8
Here we report a novel PKP2 mutation in a female proband with ARVC. In addition, 2
female relatives were identified as mutation carriers, and underwent additional clinical
screening. We report the spectrum of clinical findings in these 3 female patients with plakophilin-2 mutations.
Methods
Patients and Clinical Variables
All individuals gave written, informed consent for procedures and genetic analysis. Clinical evaluation included 12-lead electrocardiogram (ECG), signal-averaged electrocardiogram (SAECG), 2-dimensional transthoracic echocardiography, cardiac magnetic resonance
imaging (MRI), maximal exercise testing according to standard protocols, and 24-hour
ambulatory ECG monitoring. Conventional time domain criteria were used to determine an
abnormal signal-averaged ECG.12 The proband also underwent intracardiac electrophysiology study with programmed ventricular stimulation, right ventricular angiography, and
endomyocardial biopsy. Diagnosis of ARVC was based on the diagnostic criteria of the
Task Force of the European Society of Cardiology/International Society and Federation of
Cardiology.13 The criteria are given in table 1. Clinical diagnosis requires either: 2 major
criteria; 1 major plus 2 minor; or 4 minor, from different categories.
Genetic Studies
Genomic DNA was isolated from peripheral blood lymphocytes (Gentra Systems) in the
proband and in her family members. The entire cardiac RYR2 coding region (ref seq.
NM_001035, exons 1-105) and PKP2 (ref seq. NM_004572.2, exons 1-14) were screened
for mutations. Primer sequences and polymerase chain reaction (PCR) conditions are available on request. Mutational analysis of the amplicons was performed by denaturing high239
11
Clinical and Genetic Spectrum of Hereditary Cardiac Arrhythmia Syndromes
performance liquid chromatography (DHPLC, Transgenomic Wave). PCR products with
altered DHPLC peak were purified using QIAquick PCR purification kit (Qiagen) and were
sequenced bidirectionally on an ABI 377 sequencer.
11
Figure 1: 12-lead ECG of proband (top) shows low voltage in the limb leads and T-wave inversion in leads V1 to
V5. In contrast, T-wave inversion is seen only in leads V1 to V3 in the proband’s sister (bottom).
240
Results
Clinical Investigation
The proband, a previously healthy 16-year-old girl at the time of presentation, was swimming when she became lightheaded and left the pool. She then lost consciousness and
was pulseless. Rescusitation was initiated, and on paramedics arrival she was noted to be
in ventricular fibrillation. She was defibrillated successfully. Her electrocardiogram after
recovery revealed low voltage in the limb leads, T-wave inversion in leads V1-V5 (Figure
1), and normal QRS duration. Her left ventricle was normal, but her right ventricle was
enlarged with free-wall hypokinesis evident by echocardiography, MRI, and angiogram.
The right ventricular outflow tract in systole measured 28 mm in the parasternal long-axis
ECG
SAECG
Echo
MRI
Holter
Diagnostic criteria
Modified criteria for
relatives of ARVC patients
Proband
TWI V1-V5
Positive LP
Global RVE
Sister
TWI V1-V3
Negative LP
Normal
Mother
normal
Negative LP
Normal
Regional RV
HK
Regional RV
HK
Normal
1200 PVC’s
in 20 hours
238 PVC’s
24 hours
10 PVC’s 24
hours
4 minor (TWI, LP, regional
HK, Frequent PVC’s)
3 minor (TWI, regional HK, Regional HK, > 200
FH)
PVC’s, TWI
1 minor (FH only)
None
ECG indicates electrocardiogram; SAECG, signal-averaged electrocardiogram; MRI, magnetic resonance imaging; ARVC, Arrhythmogenic right ventricular cardiomyopathy; TWI, T-wave inversion; LP, late potentials; RVE,
right ventricular enlargement; HK, hypokinesis; PVC’s, premature ventricular contractions; FH, family history
Table 2: Clinical Features of Mutation Carriers
view, and 29 mm in the parasternal short-axis view. The RV medial lateral dimension in
the apical 4-chamber view in diastole was 45 mm, and in systole 38 mm. Endomyocardial
biopsy revealed focal and interstitial fibrosis with myocyte cellular and nuclear enlargement, consistent with, but not diagnostic for ARVC. Subsequent ambualtory ECG monitoring revealed frequent ventricular extrasystoles (>1,000 in 24 hours), and SAECG was
positive for late potentials. She thus fulfills criteria for clinical diagnosis of ARVC (4 minor
criteria in different diagnostic categories, see Table 2). She underwent electrophysiology
study with programmed ventricular stimulation (single, double, and triple extrastimuli at
3 drive cycle lengths from the right ventricular apex and outflow tract). She had multiple
nonsustained episodes of polymorphic ventricular tachycardia induced with double and
triple extrastimuli, and had a defibrillator implanted. She has remained free of events on
beta-blocker therapy, and is now 18 years old. She had no family history of known ARVC
or sudden unexplained death.
241
11
Clinical and Genetic Spectrum of Hereditary Cardiac Arrhythmia Syndromes
Figure 2A: Sequence analysis of the PKP2 gene shows insertion of nucleotides at c.2196 (exon 11) in proband
(arrow marked), mother and the affected sister. Black, grey, and white symbols indicate definitely affected,
possibly affected, and unaffected individuals, respectively. +/- indicates heterozygotes for the PKP2 mutation, -/indicates 2 normal PKP2 alleles.
Figure 2B: PCR amplified exon 11 of PKP2 gene, II-2 proband; I-1 father; I-2 mother; II-1 brother; II-3 sister.
Mutated allele is larger in size due to insertion of 28 nucleotides at cDNA position 2196. PCR primers used to am-
11
plify the exon 11 were 5’-CTTCATCAACCTCTGGTAATC-3’(sense) and 5’-CTTCAGCATGTACATATTACAC3’(anti-sense).
Identification of the PKP2 mutation
Screening of RYR2 (exons 1-105) did not reveal any mutations. Sequencing the PKP2 gene
revealed an insertion of 28-nucleotides at cDNA position 2196 in exon 11 which generates a frameshift in the coding region of PKP2. This results in a change in the amino acid
sequence after residue 732 in this 881-amino acid protein, with a premature stop codon
at position 740 of the mutant protein. After identification of the PKP2 mutation in the
proband, her 4 first degree relatives were screened. The same mutation was identified in the
mother and sister, but not in the father or brother (Figure 2).
Evaluation of mutation carriers
Clinical evaluation of mutation carriers included 12-lead ECG, SAECG, 2-D echocardiography, cardiac MRI, maximal exercise testing according to standard protocols, and 24-hour
242
ambulatory ECG monitoring. Invasive tests (intracardiac electrophysiology study and
right ventricular biopsy) were deferred. The patient’s mother was 45 years old at the time
of clinical investigation. Her 12-lead ECG, SAECG, echocardiogram, and cardiac MRI
were normal. She had no arrhythmias on exercise treadmill testing, or on 24-hour ambulatory ECG monitoring. She had only 10 ventricular extrasystoles in 24 hours. Aside from
a family history of ARVC based on clinical criteria in her daughter (the proband), she has
no diagnostic criteria suggestive of ARVC. At this time, she appears to be a silent mutation
carrier. The patient’s younger sister was 16 years old at the time of clinical investigation.
She had T wave inversion in leads V1-V3 (Figure 1). Her SAECG and echocardiogram
are normal. Cardiac MRI revealed mild segmental hypokinesis of the right ventricular free
wall. She had no arrhythmias on exercise testing or on 24-hour ambulatory ECG monitoring, with 238 ventricular extrasystoles in 24 hours. She presently has 3 minor criteria in
different categories for ARVC (T wave inversion, regional hypokinesis, and family history,
see Table 2). Currently, she is not being treated but has been advised to have prompt evaluation of any cardiac symptoms.
Discussion
We report the clinical findings in 3 female carriers of a novel mutation in plakophilin-2
that underlies ARVC. The proband presented with resuscitated cardiac arrest as her first
symptom, but had sufficient clinical features to make the diagnosis of ARVC at the age of
16. Of the 2 other family members with the mutation, 1 appears to be unaffected by ARVC
(a silent mutation carrier) at the age of 45. The other has several features of ARVC, and
is likely affected but does not currently meet diagnostic criteria. This report highlights
the incomplete penetrance and variable expression of ARVC, the importance of screening
first degree relatives of patients with genetic arrhythmia syndromes, the need for repeated
investigations of young patients with possible ARVC, and the limitations of the current
diagnostic criteria.
The initial report of PKP2 mutations in ARVC did not systematically evaluate familial disease in all probands. Two of the 32 kindreds in that report were available for detailed clinical analysis. In both kindreds, several mutation carriers were identified with either no or
mild disease phenotypes.8 This is consistent with our finding of incomplete penetrance of
ARVC due to plakophilin-2 mutations and recently reported findings in additional families
with PKP2 mutations.14-16 Several reasons for incomplete penetrance have been suggested,
including modifier genes, environmental triggers, and gender effects. The high proportion
of males among individuals affected with ARVC suggests that gender may have a signifi243
11
Clinical and Genetic Spectrum of Hereditary Cardiac Arrhythmia Syndromes
cant effect. We observed a wide spectrum of clinical manifestations in 3 female mutation
carriers, from no apparent disease at age 45, to ventricular fibrillation as the first symptom
at age 16. Similarly variable expression has been previously reported in ARVC due to
PKP2 mutations.14,16 This suggests that factors other than gender are important in determining penetrance of ARVC due to plakophilin-2 mutations.
It is likely that the newly identified mutation underlies ARVC in this family. The mutation causes a premature stop codon at position 740 in exon 11, and is predicted to result
in a truncated protein. Of the 25 initially decribed PKP2 mutations that underlie ARVC,
18 of them result in premature stop codons.8 Two of these previoulsy described mutations
(Q726X and R735X) result in truncations in close proximity to our novel mutation. Furthermore, a different deletion/insertion mutation that also results in a premature stop codon
at amino acid 740 has recently been reported in 6 families with ARVC in 2 separate publications.14,15 It is thought that lack of plakophilin-2 or incorporation of mutant protein into
cardiac desmosomes impairs cell to cell contact and disrupts adjacent myocytes. Mutations
that result in abnormally truncated proteins appear to be a relatively common mechanism of
PKP2 dysfunction in ARVC. Of the now 47 published PKP2 ARVC mutations, 35 result in
premature stop codons.8,14-16
11
The criteria for the clinical diagnosis of ARVD have been widely accepted, and are useful
in that they provide a uniform approach to the diagnosis of a a disease with a broad spectrum of clinical manifestations. They are, however, imperfect as a true “gold standard” for
diagnosis.17 The difference between major and minor criteria in the category of structural
alterations depends on subjective assessments, prompting the suggestion that the guidelines include quantitative measurements of right ventricular size and function.18 Further
limitations of the guidelines regarding family history are highlighted by this kindred. The
proband meets clinical criteria for diagnosis, and therefore, confers upon her relatives 1
minor criterion. If she were to have her disease “confirmed” by surgery or autopsy, her
relatives would then be assigned 1 major criterion. It is important to distinguish between
confirmed and suspected disease; however, some patients have unambiguous ARVC, but
have not had “proof” of disease by surgery or autopsy. If we consider our proband to have
“confirmed” ARVC, she would then confer a major criterion to her sister, in whom clinical
diagnosis would then be made (1 major and 2 minor criteria).
Based on prospective evaluation of family members of probands with ARVC, Hamid et al.
suggested that the diagnostic criteria be modified for first degree relatives of ARVC patients
to require only 1 minor criterion.19 Furthermore, this group recommends that the number of
244
ventricular ectopic beats required to qualify as a minor criterion may be reduced from 1,000
to 200 in a 24 hour period. Using this modified system, the proband’s sister would be considered affected, as she has 3 abnormalities (T wave inversion, > 200 PVC’s n 24 hours and
regional hypokinesis) in the context of a relative with ARVC. Although she is affected with
ARVC and at some risk for sudden death, her risk is likely lower than patients who meet
current Task Force criteria. Also, at age 16 her disease appears to be less severe than her
sister who had cardiac arrest at age 16, but who also had more ventricular ectopy, greater
degrees of RV structural abnormalities, more diffuse repolarization abnormalities, and an
abnormal SAECG. Given her lack of symptoms and mild disease at this time, we have
opted not to implant a defibrillator, but to continue close follow-up. A defibrillator will be
considered if she has progression of her disease or develops worrisome symptoms.
Although genetic testing for ARVC is not yet in widespread clinical practice, it seems inappropriate to ignore genetic information when determining disease status if available. For
example, the more broad criteria for family members of ARVC patients could be applied
to the proband’s brother and father as well. If one of these individuals had a minor ECG
abnormality, it would be inappropriate to diagnose them with ARVC, as they lack the PKP2
mutation identified in the proband. However, the diagnosis of ARVC cannot be made by
genetic information alone, as the proband’s mother appears unaffected, despite carrying the
mutation. The incomplete penetrance found in most genetic arrhythmia syndromes highlights the importance of clinical criteria. However, the current Task Force criteria are likely
too restrictive to identify patients with ARVC early in the course of the disease, while modified criteria for all family members could result in misdiagnosis of unaffected individuals.
Currently, identification of a pathogenic genetic mutation needs to be coupled with clinical
diagnostic criteria for ARVC, not only to establish the diagnosis, but also to determine the
risk for ventricular arrhythmias and to guide therapeutic decisions.
References
1.
Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation.
2004;110:1879-1884.
2.
Furlanello F, Bertoldi A, Dallago M, Furlanello C, Fernando F, Inama G, Pappone C,
3.
Chierchia S. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol. 1998;21:331-335.
Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular cardiomyopathy. J Cardiovasc Electrophysiol. 2005;16:927-935.
245
11
Clinical and Genetic Spectrum of Hereditary Cardiac Arrhythmia Syndromes
4.
Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, Bauce B, Carraro G,
Thiene G, Towbin JA. Regulatory mutations in transforming growth factor-[beta]3
gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovascular
Research. 2005;65:366-373.
5.
6.
Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo
A. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol
Genet. 2001;10:189-194.
Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R, Simionati B, Basso C, Thiene G, Towbin JA, Danieli GA. Mutation in human desmoplakin
11
domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002;71:1200-1206.
7. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G, Vettori A,
Valente M, Towbin J, Thiene G, Danieli GA, Rampazzo A. Mutations in Desmoglein-2
Gene Are Associated With Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2006;113:1171-1179.
8. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman BB, Markowitz SM, Ellinor PT, MacRae CA, Peters S, Grossmann KS, Drenckhahn J, Michely
B, Sasse-Klaassen S, Birchmeier W, Dietz R, Breithardt G, Schulze-Bahr E, Thierfelder L. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004;36:1162-1164.
9. Green KJ, Gaudry CA. Are desmosomes more than tethers for intermediate filaments?
Nat Rev Mol Cell Biol. 2000;1:208-216.
10. Mertens C, Kuhn C, Franke WW. Plakophilins 2a and 2b: constitutive proteins of dual
location in the karyoplasm and the desmosomal plaque. J Cell Biol. 1996;135:10091025.
11. Grossmann KS, Grund C, Huelsken J, Behrend M, Erdmann B, Franke WW, Birchmeier W. Requirement of plakophilin 2 for heart morphogenesis and cardiac junction
formation. J Cell Biol. 2004;167:149-160.
12. Breithardt G, Cain ME, el Sherif N, Flowers NC, Hombach V, Janse M, Simson MB,
Steinbeck G. Standards for analysis of ventricular late potentials using high-resolution
or signal-averaged electrocardiography. A statement by a Task Force Committee of the
European Society of Cardiology, the American Heart Association, and the American
College of Cardiology. Circulation. 1991;83:1481-1488.
13. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G,
Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy.
246
Task Force of the Working Group Myocardial and Pericardial Disease of the European
Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994;71:215-218.
14. Syrris P, Ward D, Asimaki A, Sen-Chowdhry S, Ebrahim HY, Evans A, Hitomi N,
Norman M, Pantazis A, Shaw AL, Elliott PM, McKenna WJ. Clinical expression of
plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy.
Circulation. 2006;113:356-364.
15. Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, Prakasa K, Towbin JA,
Marcus FI, Spevak PJ, Bluemke DA, Abraham T, Russell SD, Calkins H, Judge DP.
Clinical Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Associated With Mutations in Plakophilin-2. Circulation. 2006;113:1641-1649.
16. van Tintelen JP, Entius MM, Bhuiyan ZA, Jongbloed R, Wiesfeld ACP, Wilde AAM,
van der Smagt J, Boven LG, Mannens MMAM, van Langen IM, Hofstra RMW, Otterspoor LC, Doevendans PAFM, Rodriguez LM, van Gelder IC, Hauer RNW. Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation. 2006;113:1650-1658.
17. Scheinman MM, Crawford MH. Echocardiographic findings and the search for a gold
standard in patients with arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol. 2005;45:866-867.
18. Yoerger DM, Marcus F, Sherrill D, Calkins H, Towbin JA, Zareba W, Picard MH.
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic
right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol. 2005;45:860-865.
19. Hamid MS, Norman M, Quraishi A, Firoozi S, Thaman R, Gimeno JR, Sachdev B,
Rowland E, Elliott PM, McKenna WJ. Prospective evaluation of relatives for familial
arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden
diagnostic criteria. J Am Coll Cardiol. 2002;40:1445-1450.
247
11